en en en en en en en en en en en en en en en en en en en en en en en en en en en en en en ml en en pt fr en de nl en en en en en en en en en en en en en en en it en en en sv en en en en en en en en en en en en en en en en en en en en en en en en en en en en ml en en pt fr en de nl en en en en en en en en en en en en en en en en ms en en en fr en en en ms en en en fr en en en ms en en en fr en en en hbs_lat en en en fr en en en ms en en en fr en en en en en en en en en it en en en sv en en en en en en en en en en en en en en en en en en en en en en en en en en en en ml en en pt fr en de nl en en en en en en en en en en en en en en en en en en en en en en en en en en en en en nl en en fr en en en en en ml pt en en sv fr en en en en en en en en en en en en en en en en en en en en en gl ca en en en en en en en en en en sv es es en en en en
At this time, the APS Foundation of America provides some funding to APS ACTION and other research groups if they request assistance and we have have the funds available.
The following organizations are currently doing research on APS or related diseases. We encourage anyone who qualifies to participate in these clinical studies. By doing so, you could potentially help APS patients in the future!
APS ACTION Hydroxychloroquine Study (1)
Hospital for Special Surgery, New York, NY*
aPL-positive patients with no history of thrombosis or other systemic autoimmune diseases are randomized to receive hydroxychloroquine or no treatment in addition to their standard regimen. The study involves 11 study visits and 10 phone visits over 5 years.
Any aPL-positive patient is included in this clinical database and repository. The study involves 11 study visits and 10 phone visits over 10 years.
aPL-positive patients who are not receiving immunosuppressive treatment is included in this study that seeks to find if any particular intestinal bacteria may trigger aPL production. Participation will involve 3 study visits over a period of 2 months
Pregnant (6-11 weeks preferably, but can usually recruit up to 18 weeks), history of aPL positivity with or without SLE.
AXLN1007 in Antiphospholipid Syndrome (5)
Hospital for Special Surgery, New York, NY*
Study Title: An Open-Label Proof of Concept Phase IIa Trial of AXLN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
This is an open-label study where patients will receive 12 doses of study drug over 22 weeks for Non-criteria Manifestations of APS (low platelet count, skin ulcers or abnormal kidney function).
Navigate through Current Clinical Trials using the left and right arrows.
Founders of the APSFA
APSFA in the Media
How You Can Help
Deep Vein Thrombosis (DVT)
Transient Ischemic Attack (TIA)
INR Finger Stick Machines
The COVID-19 (Novel coronavirus) pandemic has quickly infected over a million people worldwide.  While most people with COVID-19 infections have mild or no symptoms, a significant proportion of patients can become quite ill. At this time, little is known about how patients with rheumatic diseases, many of whom use medications and drugs that suppress the immune system, are affected by the virus.  We hope to recruit adults with rheumatic diseases, and parents of children with rheumatic diseases into our study to obtain insights about how best to prevent or treat COVID-19 in this potentially vulnerable population.
Who is eligible to participate?
Adults ages 18 and over with a rheumatic disease, as well as parents of children with a rheumatic disease are eligible to enroll. Any patient from any country in the world may join our study.
Click here to take the survey: https://rheum-covid.org/patient-survey
Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.
This site complies with the HONcode standard for trustworthy health information: verify here.
Deep Vein Thrombosis (DVT)
Transient Ischemic Attack (TIA)
APS Foundation of America, Inc.
P. O. Box 801
[ Contact Form ]
DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.
If You Have Antiphospholipid Syndrome (APS) And Lupus, You May Qualify For A Research Study
If You Have Antiphospholipid Syndrome (APS) And Lupus, You May Qualify For A Research Study
The Paisley Study is a research study that is evaluating an oral investigational drug for people with moderate to severe systemic lupus erythematosus (SLE). Qualified participants must be on stable anticoagulant therapy as long as APS is not the sole or predominant feature of their SLE.
Visit PaisleyStudy.com to learn more today.
Rare Diseases Clinical Research Network
The Rare Diseases Clinical Research Network was created to facilitate collaboration among experts in many different types of rare diseases. Our goal is to contribute to the research and treatment of rare diseases by working together to identify biomarkers for disease risk, disease severity and activity, and clinical outcome, while also encouraging development of new approaches to diagnosis, prevention, and treatment.
For more information, visit rarediseasesnetwork.org.
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE)
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.
More Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00198068
Marta M. Guerra, MS
Clinical Study: Genetic Risk Factors Associated With APS
Genetic Risk Factors Associated With Antiphospholipid Syndrome (APS)
Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body’s ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk for the formation of blood clots in the lungs or deep veins of the legs, stroke, heart attack, and recurrent miscarriages. It is possible that some people with APS have a genetic predisposition for developing the syndrome. This study will use a genetic strategy to identify potential inherited risk factors for the development of APS by recruiting people with APS who have family members also affected by the syndrome or by another autoimmune disorder, such as lupus or rheumatoid arthritis.
More Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00482794
Thomas L. Ortel, MD, PhD
The primary mission of APS ACTION is to prevent, treat, and cure antiphospholipid antibody (aPL) associated clinical manifestations through high-quality, multicenter, and multidisciplinary clinical research. Their secondary mission is to refine and advance the definitions of aPL associated clinical manifestations through international collaboration and data sharing.
Their approach is simple: Members will work together to create a research alliance that will design and conduct clinical trials, and collect data via an international registry.